The extent and frequency of coagulation abnormalities in COVID-19 during pregnancy are currently unknown. Increased maternal mortality and poor obstetric outcomes have been demonstrated in association with other coronaviruses such as SARS and MERS13-15. This has not been evaluated systematically with SARS-CoV-2. The use and safety of antiviral therapies LMWH, corticosteroids in the context of COVID-19 and pregnancy is unknown.
Knowledge of the incidence of COVID-19-related coagulopathy and clinical and laboratory parameters with prognostic utility can be extremely valuable in managing pregnant women with COVID-19. This can determine the best treatment options, balancing maternal and fetal/neonatal risks and benefits, and avoiding unnecessary interventions.
The SSC for Women’ s Heath Issues in Thrombosis and Haemostasis developed this registry with the following objectives:
1- To examine coagulopathy and VTE events in COVID-19 affected pregnancies and their potential link to disease severity. To assess effects of COVID-19 related coagulopathy on maternal and fetal/neonatal outcomes
2- To study the hemostatic parameters in women with COVID-19, during each trimester of pregnancy and the postpartum period
3- To evaluate the use/effects of therapies such as LMWH, Steroids for acceleration of fetal lung maturity, antibiotics, and antivirals
Inclusion Criteria: All pregnant individuals with a confirmed COVID-19 diagnosis.
We invite all physicians and health care providers worldwide to participate in this registry. Subject to contribution, your name will be recognized in future publications wither by coauthorship or acknowledgment
A consent from the patient or their representative should be done according to your local ethics regulations. You can find a generic consent form here
If you have any questions, you may contact project leads:
Further information and project details are available on the Women's SSC site: